Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nile Therapeutics, a clinical-stage biopharmaceutical company, has announced that it will focus resources on the development of its natriuretic peptide franchise, including CD-NP which is in Phase II development for acute heart failure, and CU-NP which is a preclinical compound.
Subscribe to our email newsletter
CD-NP is a novel chimeric natriuretic peptide in clinical development for the treatment of acute heart failure. CD-NP was designed to preserve the favorable effects of current therapies while preventing or attenuating the hypotensive response, and enhancing renal function, the company said.
Results from two completed Phase I studies and the ongoing open-label Phase IIa study support advancing the CD-NP development program into a Phase IIb clinical study.
Current development plans include initiating a 30 patient placebo-controlled clinical study of acute heart failure patients with renal impairment. This study is designed to assess safety and efficacy of early administration of CD-NP in this patient population and may provide additional evidence to support the hypothesis that CD-NP enhances renal function.
Nile also announced that it will suspend the further development of 2NTX-99 and return license rights for the compound to Cesare Casagrande. 2NTX-99 is a small molecule anti-platelet, anti-atherothrombotic agent with nitric oxide donating properties.
Peter Strumph, CEO of Nile, said: We are disappointed that we are unable to continue to pursue the development of 2NTX-99. We have decided to terminate this program in order to focus our resources on our core natriuretic peptide program, which is showing great promise as a potential treatment for cardiovascular and renal disease.